Buy research grade Nirsevimab biosimilar ，anti-MEDI-8897, MEDI8897 antibody

Catalog No.

DVV02802

Expression system

Mammalian Cells

Species reactivity

HRSV-A

Host species

Humanized

Isotype

IgG1, kappa

Clonality

Monoclonal

Applications

Research Grade Biosimilar

Target

F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1

Concentration

1.64 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P03420

Form

Liquid

Storage buffer

100 mM Pro-Ac, 20 mM Arg, pH 5.0

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

MEDI-8897, MEDI8897, CAS: 1989556-22-0

Clone ID

Nirsevimab

Note

For research use only. Not suitable for clinical or therapeutic use.

Bioactivity

Detects F/Fusion glycoprotein F0 in indirect ELISAs.
SDS-PAGE

SDS PAGE for Nirsevimab
SEC-HPLC

The purity of this product is >95% as determined by SEC-HPLC.
Bioactivity

The nanomolar affinities between each antigen and Nirsevimab, as well as AM14-1, confirm their correct conformations, reflecting their varying degrees of immunogenicity.The "pre-fusogenic" BR30 prepared according to the ResVax (Novavax) methodology (GenBank: QEI22738.1), was included for comparison purpose.Annotations:* : Indicates single-chain mutation variants. # : Denotes mutants containing S46G, S215P, and K465Q.
Data sourced from citation (PMID: 39874917)
Bioactivity

Figure 4. 1G9 and 1D8 bind a similar epitope on Pre-F. (A, B) The competitive binding of Nbs 1G9 and 1D8 with six known epitope-specific antibodies. The values are normalized as competitive rates related to the negative control. Data represent the OD450 values measured and are depicted as the mean ± SD from three independent experiments. (C) The values in squares are the percent binding of the monoclonal antibody (IgG) in the presence of the competing Nbs (His-tag) relative to a mock-competition control. Source data are available online for this figure.
Data sourced from citation (PMID: 41946909)
Bioactivity

BLI profiles of BR38 (A), BR40 (B), and BR42 (C). Each column depicts interactions with Nirsevimab, D25, AM14-1, AM14-2, MPE8, and Palivizumab from top to bottom.
Data sourced from citation (PMID: 39874917)
Bioactivity

The table presents affinity coefficients of BR38, BR40, and BR42 with various mAbs. BR40 shows superior antigenicity, while BR42 demonstrates comparable performance. BR38 exhibits inferior characteristics, notably decreased affinity to AM14.Annotations:# : Denotes mutants containing S46G, A149C-Y458C, S215P and K465Q.
Data sourced from citation (PMID: 39874917)
Bioactivity

Long-term stability evaluation. (A-B) Long-term stability assessment of vaccine bulk solutions stored at 4 ℃, evaluated using (A) Nirsevimab and (B) AM14-1. BR40 and BR42 maintained higher levels of neutralizing epitope activity compared to Standard-1 and BR38, indicating superior long-term stability.
Data sourced from citation (PMID: 39874917)
Bioactivity

(A) Competitive antibody titers against Nirsevimab, showcasing the effective induction of NAbs by BR40 and BR42.
Data sourced from citation (PMID: 39874917)
Bioactivity

Each vaccine bulk solution underwent exposure to conditions of 50 ◦C/70 ◦C or pH 3.5/10.0 for 1 h, followed by evaluation of Site Ø retention using Nirsevimab.Annotations:# : Denotes mutants containing S46G, A149C-Y458C, S215P and K465Q.
Data sourced from citation (PMID: 39874917)

Broadly neutralizing nanobodies target a defined structural pivot site on the RSV fusion protein. [DVV02802]

Transamniotic Fetal Delivery of Recombinant Human Immunoglobulin Monoclonal Antibodies: A Potential Novel Strategy for Prevention of Neonatal Respiratory Syncytial Virus (RSV) Disease. [DVV02802]

Projecting maximum potential demand for nirsevimab to protect eligible US infants and young children against respiratory syncytial virus in the 2024/2025 season., PMID:40209626

Impact of routine prophylaxis with monoclonal antibodies and maternal immunisation to prevent respiratory syncytial virus hospitalisations, Lombardy region, Italy, 2024/25 season., PMID:40211969

Navigating parental hesitancy in public health: the case for RSV immunization in newborns., PMID:40216995

Summary of the National Advisory Committee on Immunization (NACI) Statement on the Prevention of Respiratory Syncytial Virus (RSV) in Infants., PMID:40241712

Global Pediatric Pulmonology Alliance recommendations to protect all infants against respiratory syncytial virus with prophylactic monoclonal antibodies., PMID:40241887

Past, present and future of respiratory syncytial infection prevention in infants and young children., PMID:40243138

Human iPS cell-derived respiratory organoids as a model for respiratory syncytial virus infection., PMID:40262853

Nirsevimab prophylaxis on pediatric intensive care hospitalization for severe acute bronchiolitis: a clinical and economic analysis., PMID:40281363

Nirsevimab immunisation of infants and respiratory syncytial virus (RSV)-associated hospitalisations, Western Australia, 2024: a population-based analysis., PMID:40293046

Impact of Nirsevimab on RSV and Non-RSV Severe Respiratory Infections in Hospitalized Infants., PMID:40302169

Nirsevimab and Maternal Respiratory Syncytial Virus Vaccine Recommendations for the Pediatric Population., PMID:40305635

Editorial: Surveillance of Seasonal Respiratory Syncytial Virus (RSV) Infection in Children and Vulnerable Adults Drives Vaccine Development and New Immunization Programs., PMID:40308086

Effectiveness of nirsevimab immunization against RSV infection in preterm infants: a systematic review and meta-analysis., PMID:40313952

Respiratory syncytial virus-related lower respiratory tract infection hospitalizations in infants receiving nirsevimab in Galicia (Spain): the NIRSE-GAL study., PMID:40314706

Cost-Effectiveness Analysis of Nirsevimab for the Prevention of Respiratory Syncytial Virus among Italian Infants., PMID:40317387

Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: a systematic review and meta-analysis., PMID:40319903

Infant Respiratory Syncytial Virus Immunization Coverage in the Vaccine Safety Datalink: 2023-2024., PMID:40324788

Knowledge, attitudes, and practices of Croatian pediatricians and pediatrics residents about RSV infection., PMID:40328920

Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products - United States, October 2024-February 2025., PMID:40338822

Estimating the impact of Western Australia's first respiratory syncytial virus immunisation program for all infants: A mathematical modelling study., PMID:40339485

RSV: an update on prevention and management., PMID:40343137

Direct Out-of-Pocket Costs of Nirsevimab vs. Palivizumab during the First Respiratory Syncytial Virus Season: A Comparative Analysis., PMID:40343422

Universal administration of nirsevimab in infants: an analysis of hospitalisations and paediatric intensive care unit admissions for RSV-associated lower respiratory tract infections., PMID:40377714

Update on Routine Immunizations for Children and Adolescents., PMID:40378322

180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial., PMID:40379431

Cost-effectiveness analysis of nirsevimab for prevention of respiratory syncytial virus disease among infants in Shanghai, China: A modeling study., PMID:40391452

Estimated impact of nirsevimab prophylaxis on the economic burden of respiratory syncytial virus disease in Northern Italy., PMID:40400006

Health-care burden related to respiratory syncytial virus in a resource-constrained setting: a prospective observational study., PMID:40412396

Maternal Perspectives on Decision-Making for Newborn RSV Prophylaxis With Nirsevimab., PMID:40413636

Respiratory syncytial virus preventives for children in Australia: current landscape and future directions., PMID:40413643

Vectored long-term co-delivery of antibodies for SARS-CoV-2, RSV and Influenza prophylaxis., PMID:40413832

Impact of Nirsevimab immunoprophylaxis on professional exhaustion during two epidemics of respiratory syncytial virus., PMID:40414172

Administration of Nirsevimab for RSV Prophylaxis in Infants: A Comprehensive Review., PMID:40432081

The potential public health impact of new immunization strategies for the prevention of RSV in children in Panama., PMID:40458968

Turkish pediatricians' knowledge, attitudes, and awareness of respiratory syncytial virus (RSV) infection and immunization strategies: a cross-sectional study., PMID:40466672

Effectiveness of immunization strategies for preventing severe acute respiratory infection during the 2023/2024 season in a Spanish health department., PMID:40467410

Respiratory syncytial virus prophylaxis for children in Africa: Challenges, opportunities and public health strategies., PMID:40469396

Intention to Use RSVpreF Vaccine or Nirsevimab to Prevent Infant RSV Among Pregnant Individuals., PMID:40472256

Nirsevimab Provides Real-World RSV Protection in Infants., PMID:40478586

Strategies to improve interprofessional communication regarding maternal and infant RSV immunization., PMID:40483884

Demographic Characteristics Associated With Uptake of Neonatal Respiratory Syncytial Virus Prophylaxis., PMID:40489377

Evaluation of pregnant women's knowledge about RSV and immunization attitudes before infant immunization with monoclonal antibodies in Turkey., PMID:40489965

Scenario Projections of Respiratory Syncytial Virus Hospitalizations Averted Due to New Immunizations., PMID:40498487

Effectiveness of nirsevimab against RSV-related outcomes: findings of the 2024-2025 campaign in Catalonia align with previous analysis., PMID:40499942

Nirsevimab: a change of paradigm in the prophylaxis of Respiratory Syncytial Virus disease among infants., PMID:40503651

Respiratory Syncytial Virus: A Narrative Review of Updates and Recent Advances in Epidemiology, Pathogenesis, Diagnosis, Management and Prevention., PMID:40507642

Effectiveness and impact of nirsevimab in Chile during the first season of a national immunisation strategy against RSV (NIRSE-CL): a retrospective observational study., PMID:40513593

Will Nirsevimab Reduce the Burden on Public Health Care?, PMID:40522634

Will Nirsevimab Reduce the Burden on Public Health Care?-Reply., PMID:40522642

Real-world uptake of nirsevimab, RSV maternal vaccine, and RSV vaccines for older adults: a systematic review and meta-analysis., PMID:40524797

Development of a genetically modified full-length human respiratory syncytial virus preF protein vaccine. [DVV02802]

Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus, PMID: 34446722

Respiratory Syncytial Virus and Human Metapneumovirus Infections in Three-Dimensional Human Airway Tissues Expose an Interesting Dichotomy in Viral Replication, Spread, and Inhibition by Neutralizing Antibodies, PMID: 32759319

Nirsevimab reduces medically attended RSV-associated lower respiratory tract infection and hospitalisations in healthy pre-term infants, PMID: 33597216

Global molecular diversity of RSV - the "INFORM RSV" study, PMID: 32591017

Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper, PMID: 34456918

Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants, PMID: 32730699

Single-dose nirsevimab prevents RSV infection, PMID: 33342497

Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants, PMID: 32726528

Document Download

Research Grade Nirsevimab.pdf

Research Grade Nirsevimab